drugset / Trial / NCT02733627
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this trial is to investigate the safety and tolerability of BI 1467335 in healthy male and female subjects following oral administration of multiple rising doses over 28 days. Secondary objectives are the exploration of the pharmacokinetics (PK) and target engagement biomarkers of BI 1467335 after multiple dosing.
Timeline
- Start
- 2016-07-07
- Primary completion
- 2017-07-12
- Completion
- 2017-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1467335 | Unknown | 10 mg | Oral |
| Subject | BI 1467335 | Unknown | 15 mg | Oral |
| Subject | BI 1467335 | Unknown | 20 mg | Oral |
Indications
No indication recorded.